A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
Latest Information Update: 22 Dec 2025
At a glance
- Drugs SHR 2906 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 22 Dec 2025 New trial record